Esperion Therapeutics, Inc.

NasdaqGM ESPR

Esperion Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -29.37%

Esperion Therapeutics, Inc. EBT Margin is -29.37% for the Trailing 12 Months (TTM) ending September 30, 2024, a 85.50% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Esperion Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -202.51%, a 40.02% change year over year.
Esperion Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -337.63%, a 20.44% change year over year.
Esperion Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -424.39%, a -819.57% change year over year.
Esperion Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -46.15%, a -60.78% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqGM: ESPR

Esperion Therapeutics, Inc.

CEO	Mr. Sheldon L. Koenig
IPO Date	June 26, 2013
Location	United States
Headquarters	3891 Ranchero Drive
Employees	240
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Key trends

Past 5 years